The aim of the study was to assess the activity and toxicity of the vinorelbine-carboplatin combination in advanced adenocarcinoma or large-cell carcinoma of the lung. The new vinca derivative, vinorelbine, shows promising activity when combined with cisplatin, but toxicity of the combination is substantial.
Methods
Accordingly, we substituted carboplatin for cisplatin in the combination in order to improve the therapeutic index. From March 1992 to March 1994, 55 untreated patients with undifferentiated unresectable or metastatic adenocarcinoma or large-cell carcinoma of the lung were recruited. The treatment consisted of a course of carboplatin (300 mg/m2) and vinorelbine (25 mg/m2) repeated every 4 weeks. The only grade 3 toxicity observed was 16 cases of grade 3 vomiting and 2 cases of grade 3 stomatitis.
Results
The positive response rate was 40% (partial response, 22 patients). In conclusion, the vinorelbine-carboplatin combination may be regarded as an active, safe regimen for the palliative treatment of advanced adenocarcinoma or large-cell carcinoma of the lung.
AdamsM., KerbyJ., RockerI., EvansA., JohansenK., FranksC.R.: A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer.Acta Oncol.,28: 57–60, 1989.
2.
ASCO Educational booklet:Multimodality therapy for stage III non-small cell lung cancer. 25th Annual Meeting, San Francisco, pp. 17–31, 1989.
3.
BensevalM.: Safety and tolerance of navelbine in phase I + II clinical studies.Semin. Oncol.,16: 37–40, 1989.
4.
BunnP.A.: Review of therapeutic trials of carboplatin in lung cancer.Semin. Oncol.,16: 27–33, 1989.
5.
BunnP.A.: The expanding role of cisplatin in the treatment of non-small-cell lung cancer.Semin. Oncol.,16: 10–21, 1989.
6.
BunnP.A.: Clinical experience with carboplatin in lung cancer.Semin. Oncol.,19: 1–11, 1989.
7.
CapewellC.: Edinburgh lung cancer group patients presenting with lung cancer in South-East Scotland.Thorax,42: 853–857, 1987.
DautzembergB.: Epidemiology and prognosis of non-small-cell lung cancer. In: Navelbine (vinorelbine). Update and New Trends. pp. 61–67, John Eurotext Ltd., Montronge, 1991.
10.
De CarliA., La VecchiaC.: Cancer mortality in Italy, 1983.Tumori,75: 196–201, 1989.
11.
DepierreA., LemaireE., DabouisG., GarniergF., JacouletP.: A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer.Am. J. Clin. Oncol.,14: 115–119, 1991.
12.
DonnadieuN., PaesmansM., SculierJ.P.: Chemotherapy of non-small-cell lung cancer according to disease extent: a metaanalysis of the literature.Lung Cancer,7: 243–252, 1991.
13.
FellousA., OhayonR., VacasinT., KrikorianA., CouzinierJ.P., MeiningerV.: Biochemical effect of navelbine on tibuline and associated proteins.Semin. Oncol.,16: 15–20, 1989.
14.
GandaraD.R., WoldH., PerezE.A.: Cisplatin dose intensity in non-small-cell lung cancer; phase II results of a day 1 and day 8 high-dose regimen.J. Natl. Cancer Inst.,81: 790–794, 1989.
15.
GrallaR.J., CasperE.S., KelsenD.P., BraunD.W.Jr, DukemanM.E.: Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules.Ann. Intern. Med.,85: 414–420, 1981.
16.
HendersonB.E., RossR.K., PikeM.C., TowardD.: The primary prevention of cancer.Science,254: 1131–1138, 1991.
17.
Klastersky J., Sculier J.P., Ravez P., Libert P., Michel J., Vendermotten G., Roomans P., Bonduelle Y., Maresse M., Michiels T., Thiriaux J., Mommen P., Dalesio O. and the EORTC Lung Cancer Working Party (Belgium):A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma.J. Clin. Oncol.,4: 1780–1786, 1986.
18.
KrikorianA., RahmaniR., BrometM., BoreP., CanoJ.P.: Pharmacokinetics and metabolism of navelbine.Semin. Oncol.,16: 21–25, 1989.
19.
KubotaK., FurusetK., NitaniH.: A late phase II study of navelbine (vinorelbine) a new vinca alkaloid active in non-small-cell lung cancer.Lung Cancer,7: 117, 1991.
20.
LebeauB., ClavierJ., KleisbauerJ.P., RebishungJ.L., MuirJ.P.: Etude de phase II de l'association navelbine-cisplatine dans le cancer broncopulmunaire non à petites cellules. In: Navelbine Actualités et perspectives. pp. 1449–1457, John Libbey Co., Ltd,Paris-London, 1990.
21.
Le ChevalierT., PujolJ.L., DouillardJ.Y., AlberdaV., MourierA.: European multicentre randomized study comparing navelbine alone vs navelbine-cisplatin vs vindesine-cisplatin in 612 patients with advanced non-small-cell lung cancer (NSCLC).Proc. Am. Soc. Clin. Oncol.,11: 189, 1992.
22.
LeviF., MezzanotteG., CongT.V., La VecchiaC.: Cancer survival from the incident cases of the registry of Vaud, Switzerland.Tumori,75: 83–89, 1989.
23.
LinA.Y., IhdeD.C.: Recent developments in the treatment of lung cancer.JAMA,267: 536–542, 1992.
24.
MalzymerA., BrunoS., PirisN., CasroC., FernandezO.: Randomized phase II trial of navelbine-cisplatin in patients with inoperable non-small-cell lung cancer.Eur. J. Cancer,27: 172, 1991.
25.
MountainC.F.: A new international staging system for lung cancer.Chest,89: 2255–2335, 1986.
26.
MuggiaF.M.: Overview of carboplatin replacing, complementing and extending the therapeutic horizons of cisplatin.Semin. Oncol.,15: 7–13, 1989.
27.
OzolsR.F., OstchegaY., MyersC.E., YoungR.C.: High-dose cisplatin in hypertonic saline in refractory ovarian cancer.J. Clin. Oncol.,3: 1246–1250, 1985.
28.
RoseL.J.: Neoadjuvant and adjuvant therapy of non-small-cell lung cancer.Semin. Oncol.,18: 536–542, 1991.
29.
RossofA.H., BeardenJ.D., ColtmanC.A.: Phase II evaluation of cis-diamminedichloro-platinum in lung cancer.Cancer Treat. Rep.,60: 1678–1680, 1979.
30.
SethiV.S.: Pharmacokinetics of vincristine, vinblastine and vindesine in rhesus monkeys.Cancer Chemother. Pharmacol.,12: 31–35, 1984.
31.
SmithI.E.: Carboplatin in small-cell lung cancer: the Royal Mardsen Hospital experience.Semin. Oncol.,19: 24–27, 1992.
32.
SorensenJ.B.: Vinorelbine: a review of its antitumor activity in lung cancer.Drugs,44: 60–65, 1992.
33.
Van EchoD.A., EroginM.J., AisnerJ.: The pharmacology of carboplatin.Semin. Oncol.,16: 1–6, 1989.
